Abstract

BackgroundPreventive chemotherapy delivered via mass drug administration (MDA) is essential for the control of neglected tropical diseases (NTDs), including lymphatic filariasis (LF), schistosomiasis and onchocerciasis. Successful MDA relies heavily on community drug distributor (CDD) volunteers as the interface between households and the health system. This study sought to document and analyse demand-side (households) and supply-side (health system) factors that affect MDA delivery in Liberia.MethodsWorking in two purposively selected counties, we conducted a household MDA access and adherence survey; a CDD survey to obtain information on direct and opportunity costs associated with MDA work; an observational survey of CDDs; and key informant surveys (KIS) with community-level health workers. Data from the CDD survey and Liberian minimum wage rates were used to calculate the opportunity cost of CDD participation per MDA round. The observational data were used to calculate the time spent on individual household-level tasks and CDD time costs per house visited. KIS data on the organisation and management of the MDA in the communities, and researcher reflections of open-ended survey responses were thematically analysed to identify key demand- and supply-side challenges.ResultsMore respondents were aware of MDA than NTD in both counties. In Bong, 39% (103/261) of respondents reported taking the MDA tablet in the last round, with “not being informed” as the most important reason for non-adherence. In Maryland, 56% (147/263) reported taking MDA with “being absent” at the time of distribution being important for non-adherence. The mean cost per CDD of participating in the MDA round was −$11.90 (median $5.04, range −$169.62 to $30.00), and the mean time per household visited was 17.14 min which equates to a mean opportunity cost of $0.03 to $0.05 per household visited. Thematic analysis identified challenges, including shortages of and delays in medicine availability; CDD frustration over costs; reporting challenges; and household concerns about drug side effects.ConclusionsImproved adherence to MDA and subsequent elimination of NTDs in Liberia would be supported by an improved medicine supply chain, financial compensation for CDDs, improved training, healthcare workforce strengthening, greater community involvement, capacity building, and community awareness.Graphical

Highlights

  • Preventive chemotherapy delivered via mass drug administration (MDA) is essential for the control of neglected tropical diseases (NTDs), including lymphatic filariasis (LF), schistosomiasis and onchocerciasis

  • This paper presents an analysis of accessibility and adherence to MDA in the post-Ebola virus disease (EVD) context from the household, community drug distributor (CDD) and health system perspective in Liberia

  • Study components We addressed the study aims through the following four components: household survey on MDA accessibility and adherence (HHS); CDD costs survey (CDD Community drug distributor cost survey (CS)); CDD observational survey during household MDA delivery (CDD Community drug distributor time and motion study (TM)); key informant surveys with health workers, community health workers and community leaders to explore community-level resources needed for MDA delivery (KIS) and a qualitative synthesis of findings (Aim 3)

Read more

Summary

Introduction

Preventive chemotherapy delivered via mass drug administration (MDA) is essential for the control of neglected tropical diseases (NTDs), including lymphatic filariasis (LF), schistosomiasis and onchocerciasis. Preventive chemotherapy delivered via mass drug administration (MDA) is essential for the control of NTDs including lymphatic filariasis (LF), schistosomiasis and onchocerciasis [2]. Onchocerciasis, LF and schistosomiasis are endemic throughout Liberia and are the most common infections among its poorest communities [7, 8] Guided by their NTD Master Plan, the Liberian Ministry of Health and partners sought to eliminate LF, onchocerciasis and schistosomiasis by 2020 [9, 10] through a combination of annual MDA with ivermectin (IVM) and albendazole (ABD); disability management and inclusion; and vector control [7]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.